Before administration, injectable medications must be sterilized. Because they are easier to carry directly into the systemic blood circulation, sterile injectable medicines are typically produced in liquid form. They may occasionally be equipped to deliver the medication to a particular area of the body. Small molecules are chemical compounds with low molecular weight that can be delivered orally or intravenously. Oncology problems, infectious diseases, blood diseases, and cardiovascular diseases are all treated with small-molecule injectable medications.
Access Full Report @ https://www.databridgemarketresearch.com/jp/reports/global-small-molecule-sterile-injectable-drug-market
The global small molecule sterile injectable drugs market is expected to reach USD 221,946.53 million by 2028 from USD 130,646.94 million in 2020, growing with a healthy CAGR of 7.2% in the forecast period of 2021 to 2028. The market for small molecule sterile injectable pharmaceuticals is expanding thanks to the rise of generic injectables. The market for small molecule sterile injectable pharmaceuticals is being held back by rising product recalls. Growing demand for small molecule sterile injectable medications is being aided by rising healthcare spending. The market for small molecule sterile injectable pharmaceuticals faces difficulties due to lack of accessibility.
Increased prevalence of infectious diseases will drive the market's growth rate
Chronic Disease Management (CDM) is ongoing care and support to assist individual impacted by a chronic health condition with the medical care, knowledge, skills, and resources they need to better manage on a day-to day-basis. Chronic diseases include Asthma, COPD and Lung Health, Brain Injury, chronic pain, dementia, diabetes, heart health, renal (kidney), stroke, and mental health among others. Chronic diseases are affecting huge number of people across the world and increase burden of chronic disease is expected to increase the demand for small molecule sterile injectable drugs. This is driving the growth of the market. Increased expenditure by public and private players on the development of infrastructure will also promote the market growth rate. Continuous research and development pertaining to the deployment of advanced technologies will yet again widen the scope of growth.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2021 to 2028
|
|
Base Year
|
2020
|
|
Historic Years
|
2019 (Customizable to 2013 - 2018)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product (Vial Filling, Syringe Filling, Cartridge Filling and Others), Application (Oncology, Infectious Diseases, Cardiovascular Diseases, Metabolic Diseases, Neurology, Dermatology, Urology, Autoimmune Diseases, Respiratory Disorders and Others), End-Users (Hospitals, Specialty Clinics, Home Care Settings and Others), Distribution Channels (Direct Tender, Retail Pharmacy, Online Pharmacy and Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Gilead Sciences, Inc. (U.S.), BIOCRYST PHARMACEUTICALS, INC. (U.S.), AstraZeneca (U.K.), Genentech, Inc. (U.S.), Merck Sharp & Dohme Corp. (Germany), Hikma Pharmaceuticals PLC (U.K.), AbbVie Inc. (U.S.), American Regent, Inc. (U.S.), Amgen Inc. (U.S.), Bristol- Myers Squibb Company (U.S.), Teligent (U.S.), Eisai Co., Ltd. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Neuren Pharmaceuticals (Australia), Noxopharm (Australia), Amomed Pharma GmbH (Austria), Sanofi (France), Exelixis, Inc. (U.S.), Fresenius Kabi USA (U.S.), Pfizer Inc. (U.S.) among others.
|
|
Data Points Covered in the Report
|
In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The small molecule sterile injectable drugs market is categorized into five notable segments which are based on the product, application, end-user, distribution channel.
- On the basis of product, the small molecule sterile injectable drugs market is segmented into vial filling, syringe filling, cartridge filling, and others. In 2021, the vial filling segment is expected to dominate the market with a 59.55% market share due to rising technological advancement in small molecule sterile injectable drugs.
- On the basis of application, the small molecule sterile injectable drugs market is segmented into oncology, infectious diseases, cardiovascular diseases, metabolic diseases, neurology, dermatology, urology, autoimmune diseases, respiratory disorders, and others. In 2021, the oncology segment is expected to dominate the market with a 30.22% market share due to the rising number of patients suffering from cancer.
- On the basis of end-users, the small molecule sterile injectable drugs market is segmented into hospitals, specialty clinics, home care settings, and others. In 2021, the hospital's segment is expected to dominate the market with a 47.67% market share due to the rising number of hospitals in developing countries.
The hospital segment will dominate the end user segment of the small molecule sterile injectable drugs market
The hospital segment will emerge as the dominating segment under end user in 2021 with approximately 47% market share. This is because of the growing number of hospitals in the market especially in the developing economies. Further, growth and expansion of the healthcare industry all around the globe will further bolster the growth of this segment.
- On the basis of distribution channels, the small molecule sterile injectable drugs market is segmented into direct tender, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment is expected to dominate the market with a 56.94% market share because the direct tender option is mostly used by the large channel hospital for purchasing small molecule sterile injectable products.
The direct tender segment will dominate the distribution channel segment of the small molecule sterile injectable drugs market
The direct tender segment will emerge as the dominating segment under distribution channel segment in 2021. This is because of the growing number of chronic diseases and infections all over the globe. Further, growth and expansion of research development services on a global scale will further bolster the growth of this segment.
Major Players
Data Bridge Market Research recognizes the following companies as the market players in small molecule sterile injectable drugs market: Gilead Sciences, Inc. (U.S.), BIOCRYST PHARMACEUTICALS, INC. (U.S.), AstraZeneca (U.K.), Genentech, Inc. (U.S.), Merck Sharp & Dohme Corp. (Germany), Hikma Pharmaceuticals PLC (U.K.), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Neuren Pharmaceuticals (Australia), Noxopharm (Australia), Amomed Pharma GmbH (Austria), Sanofi (France), Exelixis, Inc. (U.S.), Fresenius Kabi USA (U.S.) and Pfizer Inc. (U.S.).
Market Development
- In May 2020, AbbVie Inc. acquired Allergan; a global company focused on manufacturing products targeting neuroscience, urology among other medical fields. This acquisition allowed the company to enhance its therapeutic categories and strengthen the company's financial values, which ultimately accelerated the company's research and developmental activities.
- In April 2021, WellSky launched an advanced home health visit management solution. The new addition CareInsights Guidance provides actionable visit utilization insights to balance the care quality and patient health improvement. It is predicted that this solution launch will provide benefits to their patients, staff and leading to an upsurge in the sales growth of the company.
Regional Analysis
Geographically, the countries covered in the small molecule sterile injectable drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
As per Data Bridge Market Research analysis:
North America is the dominant region in small molecule sterile injectable drugs market during the forecast period 2021 - 2028
Because of the substantial investment in the region for adopting new healthcare facilities, North America is likely to lead the global market. In addition, the region's market is fueled by the presence of major competitors, increase in need for support from clinical laboratory services for efficient treatment and patient care within the region and early adoption of advanced products.
Asia-Pacific is estimated to be the fastest-growing region in small molecule sterile injectable drugs market the forecast period 2021 - 2028
Asia-Pacific is expected to increase significantly as well and will register the highest growth rate owing to an increase in the region's pet population and increased investments in the healthcare sector. Furthermore, as part of their economic growth aspirations, growing economies in APAC, such as India, are heavily investing in the infrastructure development. Furthermore, due to the growing unmet medical needs increasing scientific research in the region and increasing investment by multiple organizations in product research and development, particularly in manufacturing in developing countries, is fueling market expansion in the region.
COVID-19 Impact Analysis
Workflows in the worldwide healthcare industry have been hampered by the COVID-19 epidemic. Numerous companies, including parts of the healthcare industry, have been forced to temporarily close their doors due of the disease. The COVID-19 epidemic had a detrimental overall effect on major companies in the injectable business. In the context of the market, the COVID-19 pandemic has caused supply chain interruptions and a delay in production. The demand for product sterilization services has increased as a result, nevertheless. Due to a sharp rise of COVID-19 cases worldwide, countries were forced to close their manufacturing facilities and create quarantine zones in order to control the spread, which had a detrimental effect on the businesses that make medical devices.
For more detailed information about the small molecule sterile injectable drugs on market report, click here – https://www.databridgemarketresearch.com/jp/reports/global-small-molecule-sterile-injectable-drug-market
